"While standard at-home ovulation tests predict fertile days by tracking estrogen and Luteinizing hormone (LH), they don't measure the hormone that confirms your ovulation, which is progesterone metabolite PdG. Inito allows women to measure estrogen, LH, progesterone (PdG), and FSH on a single test strip. Inito's AI models interpret these levels to reveal fertility hormone patterns, track fertile days, and confirm ovulation."
"For context, when you take a test at a lab or a home, antibodies are what bind to the target molecule (such as estrogen or testosterone) to produce a signal. Traditional antibodies are grown inside animals and then screened manually in the lab, which can be a slow and expensive process. Conventional antibodies also lack the sensitivity to make at-home tests for a large number of biomarkers."
Inito raised $29 million in Series B funding to scale an at-home health diagnostics platform and develop AI-designed antibodies for new home tests. The company launched its first fertility monitor in 2021 to enable quantitative at-home hormone testing. The device measures estrogen, LH, progesterone metabolite PdG, and FSH on a single strip, and uses AI models to interpret levels, reveal hormone patterns, track fertile days, and confirm ovulation. Inito has analyzed more than 30 million fertility hormone data points since 2021. The new funding will support expanding from fertility tracking into broader hormone and at-home diagnostics by engineering synthetic antibodies with AI.
Read at TechCrunch
Unable to calculate read time
Collection
[
|
...
]